<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04493073</url>
  </required_header>
  <id_info>
    <org_study_id>OCTA after Trabeculectomy</org_study_id>
    <nct_id>NCT04493073</nct_id>
  </id_info>
  <brief_title>Conjunctival Vascularity Changes Usnig OCTA After Trabeculectomy</brief_title>
  <official_title>Comparison of Conjunctival Vascularity Changes Using Optical Coherence Tomography Angiography After Trabeculectomy With Mitomycin and Ologen Implants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asmaa Ahmed Ali Youssif</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Reduce the trauma and the time taken for patient rehabilitation.&#xD;
&#xD;
        -  The prevailing trend is to perform a mitomycin- C (MMC)-augmented trabeculectomy and&#xD;
           trabeculectomy with ologen implants in a trial to decrease bleb failure as a common&#xD;
           post- trabeculectomy complication.&#xD;
&#xD;
        -  Is to develop a measurement protocol by OCT-A imaging and characterization of the bleb&#xD;
           vascularity changes in glaucoma patients before and after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this project is to compare bleb vascularity changes using optical&#xD;
      coherence tomography (OCT-A) between mitomycin- C (MMC)-augmented trabeculectomy and develop&#xD;
      trabeculectomy with ologen implants to determine whether bleb vascularity measurements during&#xD;
      preoperative and early postoperative periode could act as surrogate parameters to predict&#xD;
      surgical outcomes.&#xD;
&#xD;
      Glaucoma often existent in the elderly population. Measuremets of bleb vascularity beginning&#xD;
      to become an essential part of the glaucoma specialist's clinical and operative took. As&#xD;
      investigators continue to collect data both clinically and in the laboratory, these various&#xD;
      imaging modalities will shepherd surgeons into a more precise and predicable era of glaucoma&#xD;
      surgeries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>conjunctival vascularity changes</measure>
    <time_frame>1 year</time_frame>
    <description>conjunctival vascularity changes using OCTA</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>OCTA</condition>
  <arm_group>
    <arm_group_label>Trabectulectomy with mitomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India) 10 mg vial 2 mg/ml concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trabectulectomy with Ologen implants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ologen Collagen Implant (Aeon Astron Europe, Netherlands) - three-dimensional collagen- GAG implant &gt;90% lyophilized porcine atelocollagen and &lt;10% lyophilized porcine GAG 12 mm in diameter with 1 mm of thickness and 6 mm in diameter with 2 mm of thickness</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabectulectomy</intervention_name>
    <description>decrease IOP</description>
    <arm_group_label>Trabectulectomy with Ologen implants</arm_group_label>
    <arm_group_label>Trabectulectomy with mitomycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin</intervention_name>
    <description>Decrease bleb failure</description>
    <arm_group_label>Trabectulectomy with mitomycin</arm_group_label>
    <other_name>ologen implants</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ologen Collagen Implant</intervention_name>
    <description>Ologen Collagen Implant (Aeon Astron Europe, Netherlands)</description>
    <arm_group_label>Trabectulectomy with Ologen implants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitomycin-C Kyowa®</intervention_name>
    <description>Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India)</description>
    <arm_group_label>Trabectulectomy with mitomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients older than 18 years of age with primary or secondary open-angle glaucoma.&#xD;
&#xD;
          -  Primary OAG (POAG) diagnosed on the basis of IOP measurements more than 21 mmHg, open&#xD;
             angle on gonioscopy (Grade 3 or 4 on Schaffer grading system for angle width),&#xD;
             glaucomatous visual field defects consistent with glaucomatous optic disc changes.&#xD;
&#xD;
          -  PNAG was diagnosed by the presence of narrow or occludable angle on gonioscopy (Grade&#xD;
             2, or 1 on Schaffer grading system for angle width in at least 180° of the total&#xD;
             circumference of the angle in primary position without indentation), glaucomatous&#xD;
             optic disc changes, visual field defects and IOP more than 21 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or lactating female.&#xD;
&#xD;
          -  previous intraocular surgery&#xD;
&#xD;
          -  one-eyed patients.&#xD;
&#xD;
          -  previous ocular trauma.&#xD;
&#xD;
          -  uveitis-induced glaucoma, neovascular glaucoma, aphakic/pseudophakic glaucoma&#xD;
&#xD;
          -  systemic connective tissue disease and missing more than 3 follow-up visits.&#xD;
&#xD;
          -  Trabeculectomy augmented by either MMC or Ologen implant was indicated to study&#xD;
             subjects if they had uncontrolled IOP under maximum antiglaucoma medications (3&#xD;
             antiglaucoma drugs) or due to poor socioeconomic status.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Saad</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asmaa Ali, PhD</last_name>
    <phone>01002475442</phone>
    <email>asmaaahmedali@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Khaled Abd El azzem, PhD</last_name>
    <phone>01114001717</phone>
  </overall_contact_backup>
  <reference>
    <citation>He M, Wang W, Zhang X, Huang W. Ologen implant versus mitomycin C for trabeculectomy: a systematic review and meta-analysis. PLoS One. 2014 Jan 20;9(1):e85782. doi: 10.1371/journal.pone.0085782. eCollection 2014. Review.</citation>
    <PMID>24465704</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Asmaa Ahmed Ali Youssif</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

